KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study
Annals of Hematology · 10.06.2026 · 105 (9)
DOI: 10.1007/s00277-026-07112-y ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 10.06.2026. Verfasst von Yongzhi Zheng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paeditric Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union H…. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-kit, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Fujian Province, Fujian Provincial Clinical Research Center for Hematological Malignancies.
Abstract (Originalsprache)
Although core-binding factor acute myeloid leukemia (CBF-AML) is generally considered a favorable-risk subtype in children, disease relapse remains a significant concern. The prognostic relevance of co-occurring mutations, particularly KIT and FLT3-ITD, remains debatable, and treatment intensity may modulate their impact. This multicenter analysis included 289 children (< 14 years) with newly diagnosed CBF-AML enrolled in the C-HUANAN-AML-15 study (2015-2023). KIT and FLT3-ITD mutations were identified via cytogenetic analysis and targeted sequencing. Measurable residual disease (MRD) was evaluated by multiparameter flow cytometry (MFC) and quantitative polymerase chain reaction (PCR) following induction chemotherapy. Survival analyses were performed using Kaplan-Meier and Cox regression methods. This multicenter analysis included 289 children (< 14 years) with newly diagnosed CBF-AML enrolled in the C-HUANAN-AML-15 study (2015-2023). KIT and FLT3-ITD mutations were identified via cytogenetic analysis and targeted sequencing. Measurable residual disease (MRD) was evaluated by multiparameter flow cytometry (MFC) and quantitative polymerase chain reaction (PCR) following induction chemotherapy. Survival analyses were performed using Kaplan-Meier and Cox regression methods. KIT mutations were detected in 103 patients (35.6%), predominantly involving exon 17 (69.9%), and were associated with extramedullary disease, sex chromosome loss, and trisomy 22. No significant differences in 5-year event-free survival (EFS), overall survival (OS), or cumulative incidence of relapse (CIR) were observed between patients with and without KIT mutations. FLT3-ITD mutations (5.5% of patients) did not adversely affect outcomes. Neither mutation independently predicted survival. MRD positivity (MFC-MRD ≥ 0.1%) after the second induction cycle strongly predicted inferior EFS and OS and higher CIR, with corresponding results observed for molecular MRD and parallel findings for PCR-based MRD. In this large multicenter cohort, KIT and FLT3-ITD mutations did not adversely affect the prognosis of pediatric CBF-AML treated according to the C-HUANAN-AML-15 protocol. MRD after induction was the most powerful predictor of relapse and survival, underscoring its importance for risk stratification in future pediatric AML trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paeditric Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
- Department of Pediatrics, Zhujiang Hospital of Southern Medical University, No. 253, Gongye Avenue Middle, Guangzhou, Guangdong Province, China.
- Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Nanfang-Chunfu Children's Institute of Hematology & Oncology, TaiXin Hospital, Dongguan, China.
- Department of Pediatric Hematology/Oncology, Hematology and Oncology, Hunan Children's Hospital, Changsha, China.
- Department of Pediatric Hematology/Oncology, Shenzhen Children's Hospital, Shenzhen, China.
Förderung
- Natural Science Foundation of Fujian Province
- Fujian Provincial Clinical Research Center for Hematological Malignancies
Zitieren
APA
Zheng, Y., Yu, L., Le, S., Li, N., Feng, X., Li, C., Zheng, M., Mai, H., Jiang, H., He, X., Wen, H., Xu, H., Chen, C., & Yang, L. (2026). KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study. Annals of Hematology, 105(9). https://doi.org/10.1007/s00277-026-07112-y
Vancouver
Zheng Y, Yu L, Le S, Li N, Feng X, Li C, et al. KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study. Annals of Hematology. 2026;105(9). doi:10.1007/s00277-026-07112-y
BibTeX
@article{Zheng2026,
author = {Zheng, Yongzhi and Yu, Lihua and Le, Shaohua and Li, Nainong and Feng, Xiaoqin and Li, Chunfu and Zheng, Mincui and Mai, Huirong and Jiang, Hua and He, Xiangling and Wen, Hong and Xu, Honggui and Chen, Chun and Yang, Lihua},
title = {KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {9},
doi = {10.1007/s00277-026-07112-y}
}
EUVIMED